Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Xilio Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Xilio Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Shannon James Samuel | Director | 10,000 | Jun 12, 2026 | 2 |
| Bonstein Sara | Director | – | Jun 12, 2026 | 1 |
| Brennan Aoife | Director | – | Jun 12, 2026 | 1 |
| Ross Robert W. | Director | – | Jun 12, 2026 | 1 |
| Xu Yuan | Director | – | Jun 12, 2026 | 1 |
| Curran Daniel J. | Director | – | Jun 12, 2026 | 1 |
| Bello Akintunde Olatokumbo | Director | – | Jun 12, 2026 | 1 |
| Blanchard Cheryl R | Director | – | Apr 16, 2026 | 1 |
| Gilead Sciences, Inc. | 10% Owner | 9,105,451 | Feb 17, 2026 | 2 |
| Russo Rene | PRESIDENT AND CEO | 325,422 | Jan 5, 2026 | 2 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | 6,371 | Jan 5, 2026 | 2 |
| Frankenfield Christopher James | Chief Financial Officer | 24,766 | Jan 5, 2026 | 2 |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | 33,250 | Jan 5, 2026 | 2 |
| Clancy Paul J | Director | – | Jun 12, 2025 | 0 |
| Rossi Christina | Director | – | Jun 12, 2025 | 0 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 734,546Indirect | Feb 9, 2024 | 0 |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | 734,546Indirect | Feb 9, 2024 | 0 |
| Atlas Venture Associates Opportunity I, L.P. | 10% Owner | 734,546Indirect | Feb 9, 2024 | 0 |
| Atlas Venture Associates Opportunity I, LLC | 10% Owner | 734,546Indirect | Feb 9, 2024 | 0 |
| Atlas Venture Associates XI, LLC | 10% Owner | 734,546Indirect | Feb 9, 2024 | 0 |
| Atlas Venture Associates XI, L.P. | 10% Owner | 734,546Indirect | Feb 9, 2024 | 0 |
| Huber Martin H. Jr. | PRESIDENT AND HEAD OF R&D | – | Aug 18, 2023 | 0 |
| Heyman Tomas J. | Director | – | Jun 13, 2023 | 0 |
| English Edward C | PRINCIPAL ACCOUNTING OFFICER | – | Jan 4, 2023 | 0 |
| Ross Michael Jay | Director | – | Jun 17, 2022 | 0 |
| Giovine Salvatore | CHIEF FINANCIAL OFFICER | – | Feb 24, 2022 | 0 |
| BCIP Life Sciences Associates, LP | 10% Owner | 2,805,413Indirect | Dec 10, 2021 | 0 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 2,805,413Indirect | Dec 10, 2021 | 0 |
| Bain Capital Life Sciences Fund II, L.P. | 10% Owner | 2,805,413Indirect | Dec 10, 2021 | 0 |
| Bain Capital Life Sciences Investors II, LLC | 10% Owner | 2,805,413Indirect | Dec 10, 2021 | 0 |
| BCLS II Investco, LP | 10% Owner | 2,805,413Indirect | Dec 10, 2021 | 0 |
| BCLS II Investco (GP), LLC | 10% Owner | 2,805,413Indirect | Dec 10, 2021 | 0 |
| SV7 Impact Medicine Fund LP | 10% Owner | 1,613,632Indirect | Nov 3, 2021 | 0 |
| SV7 (Imf) GP LLP | 10% Owner | 1,613,632Indirect | Nov 3, 2021 | 0 |
| Deerfield Management Company, L.P. | 10% Owner, Other: Possible Member of 10% Group | 1,143,972Indirect | Oct 28, 2021 | 0 |
| Deerfield Mgmt L.P. | 10% Owner, Other: Possible Member of 10% Group | 1,143,972Indirect | Oct 28, 2021 | 0 |
| Deerfield Partners, L.P. | 10% Owner, Other: Possible Member of 10% Group | 1,143,972Indirect | Oct 28, 2021 | 0 |
| Flynn James E | 10% Owner, Other: Possible Member of 10% Group | 1,143,972Indirect | Oct 28, 2021 | 0 |
| Deerfield Mgmt V, L.P. | 10% Owner, Other: Possible Member of 10% Group | 1,143,972Indirect | Oct 28, 2021 | 0 |
| FMR LLC | Other: See Remark 1 | 4,465Indirect | Oct 28, 2021 | 0 |
| FIL Ltd | Other: See Remark 1 | 218,705Indirect | Oct 28, 2021 | 0 |
| Takeda Pharmaceutical Co Ltd | 10% Owner | 1,475,121Indirect | Oct 26, 2021 | 0 |
| Takeda Ventures, Inc. | 10% Owner | 1,475,121Indirect | Oct 26, 2021 | 0 |
| Rock Springs Capital Management LP | 10% Owner | 1,256,472Indirect | Oct 26, 2021 | 0 |
| Rock Springs Capital Master Fund LP | 10% Owner | 1,256,472Indirect | Oct 26, 2021 | 0 |
| Rock Springs Capital LLC | 10% Owner | 1,256,472Indirect | Oct 26, 2021 | 0 |
| Four Pines Master Fund LP | 10% Owner | 1,256,472Indirect | Oct 26, 2021 | 0 |
| Bay City Capital LLC | 10% Owner | 1,129,490Indirect | Oct 26, 2021 | 0 |
| Alexandria Venture Investments, LLC | 10% Owner | 166,423 | Oct 26, 2021 | 0 |
| RiverVest Venture Fund IV, L.P. | 10% Owner | 1,441,444Indirect | Oct 26, 2021 | 0 |
Showing the 50 most recent filers.
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | Shannon James SamuelDirector | PPurchase | +5.00K | $8.79 | +$44.0K | +100.0%10.0K after | |
| Feb 17, 2026 (view filing) | Feb 13 | 4 days | Gilead Sciences, Inc.10% Owner | PPurchase | +3.74M | $0.53 | +$1.98M | –40.4M after | Derivative |
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | SSale | −1.83K | $0.64 | −$1.17K | −22.3%6.37K after | 10b5-1 |
| Jan 5, 2026 (view filing) | Jan 2 | 3 days | Frankenfield Christopher JamesChief Financial Officer | SSale | −7.03K | $0.64 | −$4.50K | −22.1%24.8K after | 10b5-1 |
| Jun 18, 2025 (view filing) | Jun 16-17 | 2 days | Shannon James SamuelDirector | PPurchase | +70.0K | $0.69 | +$48.3K | New position70.0K after | 2 lots |
| Jun 18, 2025 (view filing) | Jun 16 | 2 days | Russo RenePRESIDENT AND CEO | PPurchase | +36.3K | $0.68 | +$24.7K | +14.8%281.2K after | |
| Jun 6, 2025 (view filing) | Jun 5 | 1 day | Gilead Sciences, Inc.10% Owner | PPurchase | +53.3M | – | – | –13.3M after | Derivative4 lots |
| Jan 3, 2025 (view filing) | Jan 2 | 1 day | Frankenfield Christopher JamesChief Financial Officer | SSale | −6.95K | $0.98 | −$6.81K | −35.9%12.4K after | 10b5-1 |
| Jan 3, 2025 (view filing) | Jan 2 | 1 day | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | SSale | −1.80K | $0.98 | −$1.77K | −36.1%3.20K after | 10b5-1 |
| Dec 19, 2024 (view filing) | Dec 18 | 1 day | Gilead Sciences, Inc.10% Owner | PPurchase | +1.76M | $1.04 | +$1.83M | +24.0%9.11M after | |
| Dec 19, 2024 (view filing) | Dec 18 | 1 day | Gilead Sciences, Inc.10% Owner | PPurchase | +6.09M | $1.04 | +$6.34M | –9.98M after | Derivative |
| Apr 3, 2024 (view filing) | Apr 2 | 1 day | Gilead Sciences, Inc.10% Owner | PPurchase | +485.3K | $0.76 | +$368.8K | +7.1%7.35M after | |
| Apr 3, 2024 (view filing) | Apr 2 | 1 day | Gilead Sciences, Inc.10% Owner | PPurchase | +3.88M | $0.76 | +$2.95M | –3.88M after | Derivative |
| Feb 9, 2024 (view filing)4:33 PM ET | Feb 8 | 1 day | Atlas Venture Fund XI, L.P. and 5 others10% Owner | SSale | −733 | $0.64 | −$469.12 | 0.0%2.02M after | |
| Feb 9, 2024 (view filing)4:33 PM ET | Feb 8 | 1 day | Atlas Venture Fund XI, L.P. and 5 others10% Owner | SSale | −267 | $0.64 | −$170.88 | 0.0%734.5K after | |
| Jan 16, 2024 (view filing)6:16 PM ET | Jan 11-12 | 5 days | Atlas Venture Fund XI, L.P. and 5 others10% Owner | SSale | −3.11K | $0.8502 | −$2.64K | −0.2%2.02M after | 2 lots |
| Jan 16, 2024 (view filing)6:16 PM ET | Jan 11-12 | 5 days | Atlas Venture Fund XI, L.P. and 5 others10% Owner | SSale | −1.13K | $0.8502 | −$959.83 | −0.2%734.8K after | 2 lots |
| Dec 10, 2021 (view filing)8:33 PM ET | Dec 8-10 | 2 days | BCIP Life Sciences Associates, LP and 5 others10% Owner | PPurchase | +42.5K | $9.66 | +$410.2K | +1.5%2.81M after | 4 lots |
| Nov 3, 2021 (view filing)4:20 PM ET | Oct 26 | 8 days | SV7 Impact Medicine Fund LP and 1 other10% Owner | PPurchase | +312.5K | $16.00 | +$5.00M | +24.0%1.61M after | Amended |
| Nov 3, 2021 (view filing)4:20 PM ET | Oct 26 | 8 days | SV7 Impact Medicine Fund LP and 1 other10% Owner | PPurchase | +312.5K | $16.00 | +$5.00M | +24.0%1.61M after | Amended |
| Oct 28, 2021 (view filing)7:15 PM ET | Oct 26 | 2 days | Deerfield Management Company, L.P. and 4 others10% Owner, Other: Possible Member of 10% Group | PPurchase | +775.0K | $16.00 | +$12.4M | +210.0%1.14M after | 2 lots |
| Oct 26, 2021 (view filing)5:04 PM ET | Oct 26 | Same day | Rock Springs Capital Management LP and 3 others10% Owner | PPurchase | +500.0K | $16.00 | +$8.00M | +66.1%1.26M after | |
| Oct 26, 2021 (view filing)5:01 PM ET | Oct 26 | Same day | Atlas Venture Fund XI, L.P. and 1 other10% Owner | PPurchase | +187.5K | $16.00 | +$3.00M | +34.2%735.9K after | |
| Oct 26, 2021 (view filing) | Oct 26 | Same day | Bay City Capital LLC10% Owner | PPurchase | +312.5K | $16.00 | +$5.00M | +38.3%1.13M after | |
| Oct 26, 2021 (view filing) | Oct 26 | Same day | RiverVest Venture Fund IV, L.P.10% Owner | PPurchase | +250.0K | $16.00 | +$4.00M | +21.0%1.44M after |